<DOC>
	<DOCNO>NCT00271817</DOCNO>
	<brief_summary>To evaluate efficacy safety ezetimibe/simvastatin niacin patient high cholesterol .</brief_summary>
	<brief_title>To Evaluate Ezetimibe/Simvastatin Niacin ( Extended Release Tablet ) Patients With Type IIa Type IIb Hyperlipidemia ( 0653A-091 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patient LDLC 130 190 mg/dL Triglycerides le equal 500 mg/dL Patient willing lowcholesterol diet Pregnant lactate woman intend become pregnant Patient sensitivity intolerance ezetimibe , simvastatin , ezetimibe/simvastatin combination tablet Patient sensitivity intolerance ro niacin , component niacin extend release aspirin Patient discontinuation exist lipidlowering therapy treatment pose unacceptable risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>